Novavax COVID-19 vaccine study now includes kids, company says
Fox News
Vaccine development company Novavax on Monday announced it has expanded its Phase 3 clinical trial for its COVID-19 vaccine to children between the ages of 12 and 17.
"Two-thirds of volunteers will receive intramuscular injections of the vaccine and one-third will receive placebo. A blinded crossover is planned to take place six months after the initial set of vaccinations to ensure that all trial participants receive active vaccine," the company said in a news release. "Participants will be monitored for safety for up to two years following the final dose." In late January, Novavax announced its protein-based vaccine showed 89.3% efficacy against coronavirus in a U.K.-based trial, which it noted was during a peak period of transmission and when the B.1.1.7 variant was in circulation.More Related News